Clinical responses to T(n)BP-disrupted HDCS (WI-38) rabies vaccine.
Study of 10 batches of an antirabies vaccine made from purified, concentrated subunits (Pitman-Moore strain adapted to Wistar HDCS). One single dose of vaccine is insufficient; three or more doses induce high antibody levels. Among more than 2000 vaccines secondary reactions were rare and generally mild and transient. All the individuals vaccinated post-exposure remained without rabic symptoms. The vaccine was also particularly efficacious for booster doses.
D000914:Antibodies, Viral / Q000096:biosynthesis*; D006801:Humans; D007115:Immunization Schedule; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D011820:Rabies virus / Q000276:immunology*; D013223:Statistics as Topic
D000914:Antibodies, Viral; D011819:Rabies Vaccines